Phaseline

Companies › Atea Pharmaceuticals

Atea Pharmaceuticals: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 3 Phase 1, 2 Phase 3; Infectious disease, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Bemnifosbuvir-Ruzasvir (BEM/RZR)
HCV NS5B polymerase inhibitor and NS5A inhibitor combination
NS5B, NS5APhase 3HEPATITIS C VIRUS CHRONIC INFECTIONDec 2026
AT-587–Phase 1Hepatitis EDec 2026
Bemnifosbuvir (BEM, AT-527)
Nucleoside reverse transcriptase inhibitor
–Phase 1Healthy Volunteer Study–
Ruzasvir (AT-038)
Nonstructural protein 5A inhibitor
–Phase 1Healthy Volunteer Study–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06868264Bemnifosbuvir-Ruzasvir (BEM/RZR)Phase 3HEPATITIS C VIRUS CHRONIC INFECTIONInfectious diseaseJun 2026
NCT07314346Bemnifosbuvir (BEM, AT-527)Phase 1Healthy Volunteer StudyOtherJul 2026
NCT07314346Ruzasvir (AT-038)Phase 1Healthy Volunteer StudyOtherJul 2026
NCT07728487AT-587Phase 1Hepatitis EInfectious diseaseDec 2026
NCT07037277Bemnifosbuvir-Ruzasvir (BEM/RZR)Phase 3HEPATITIS C VIRUS CHRONIC INFECTIONInfectious diseaseDec 2026

From the company's SEC filings

Cash and short-term investments of $191m on 2026-09-30; operating cash outflow about $151m a year; runway about 15 months at that burn, to Jan 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

NS5B (1) NS5A (1)

Companies with the same targets

–

Companies built like this

Shanghai Ark Biopharmaceutical Ensysce Biosciences Aligos Therapeutics BioAegis Therapeutics Basilea Pharmaceutica

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.